Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. May 27, 2014; 6(5): 284-292
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.284
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.284
Resistance | Action |
LAM resistance | Switch to TDF (add ADV if TDF not available) |
ADV resistance | If patient was NA naive before ADV: switch to ETV or TDF; |
ETV may be preferred in such patients with high viremia | |
If patient had prior LAM resistance: switch to TDF and add a nucleoside analogue | |
LdT resistance | Switch to or add TDF (add ADV if TDF not available) |
ETV resistance | Switch to or add TDF (add ADV if TDF not available) |
TDF resistance | TDF resistance not detected to date: add a nucleoside analogue |
Switch to ETV if patient had no prior LAM resistance or add ETV in patients with LAM resistance |
- Citation: Santantonio TA, Fasano M. Chronic hepatitis B: Advances in treatment. World J Hepatol 2014; 6(5): 284-292
- URL: https://www.wjgnet.com/1948-5182/full/v6/i5/284.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i5.284